Objective response rate across all 29 participants was 32.1%; Favorable disease control rate (92.9%) across all participants was observed Data suggest that the combination of Ixo-V and bevacizumab may ...
Morning Overview on MSN
A new drug combo shrank treatment-resistant colon cancer in a large clinical trial
Patients with metastatic colorectal cancer that had stopped responding to at least two prior treatment regimens gained meaningful extra months of life when bevacizumab was added to the chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results